LH earnings

Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships

BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024:Revenue: $3.56 billion versus $3.28 billionDiluted EPS: $3.12 versus $2.00Adjusted EPS: $4.18 versus $3.50Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timingAdjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 millionSigned several strategic agreements with health systems and regional/local laboratoriesAdvanced business in high-growth specialty testing areas, including onco

BURLINGTON, N.C., Sept. 25, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

Company Provides 2025 Guidance Results from Continuing Operations versus last year:Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 millionAnnounced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024Full-Year 2025 Guidance:Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%Free Ca

BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Particip

Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesBURLINGTON, N.C., Oct. 24, 2024 /PRNewswire/ -- Labcorp

BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year:Revenue: $3.22 billion versus $3.03 billionDiluted EPS: $2.43 versus $1.74Adjusted EPS: $3.94 versus $3.42Free Cash Flow: $432.9 million versus $58.2 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0%Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 millionShare repurchase authorization increased by $1.0 billion to $1.4 billionLaunched important new tests in specialty testing areasIntroduced Labcorp Global Trial Connect, a suite

BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also re

Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS: $2.69 versus $2.34Adjusted EPS: $3.68 versus $3.46Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35; Free Cash Flow remains $1.00 billion to $1.15 billionYear to date announced/completed five acquisitions that support our strategySignificantly expanded our test menu in key therapeutic areasBURLINGTON, N.C., April 25, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced results for the

BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also r

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year:Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billionDiluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million vs $1.34 billionAnnounced six new laboratory partnerships and launched new innovative tests in our focused specialty areas across the business in 2023Full Year 2024 Guidance: Adjusted EPS of $14.30 to $15.40 and Free Cash Flow of $1.00 billion to $1.15 billionBURLINGTON,

BURLINGTON, N.C., Jan. 16, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participa

BURLINGTON, N.C., Sept. 29, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30, which is treated as discontinued operations in the historical financialsAnnounced a $1.0 billion accelerated share repurchase programDrove growth through new and expanded healthcare system partnershipsSecond quarter revenue grew 4% versus last year as the Base Business grew 13%. Results from Continuing Operations for second quarter versus last year:Revenue: $3.0 billion versus $2.9 billionDiluted EPS: $1.74 versus $2.89Adjusted EPS: $3.42 versus $4.04Free Cash Flow: $177 million versus $408 millionFull-Year 2023 Guidance from Continuing Operations: Adjusted EPS of $13.00 to $14.00 and Free Cash Flow of

BURLINGTON, N.C., June 29, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the second quarter of 2023 before the market opens on Thursday, July 27, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicki

Company Updates Full-Year Guidance First quarter Base Business revenue grew 10%, while total revenue and earnings were down due to COVID-19 TestingRevenue: Q1 of $3.8 billion versus $3.9 billion last yearDiluted EPS: Q1 of $2.39 versus $5.23 last yearAdjusted EPS: Q1 of $3.82 versus $6.11 last yearFree Cash Flow: Q1 of $27 million versus $239 million last yearPlanned spin of Clinical Development business remains on schedule for mid-2023Full-Year 2023 Guidance: Adjusted EPS narrowed to $16.25 to $17.75 with midpoint unchanged and Free Cash Flow remains at $1.0 billion to $1.2 billionBURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a leading global life sciences company, tod

BURLINGTON, N.C., March 31, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the first quarter of 2023 before the market opens on Tuesday, April 25, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicki

Company Provides 2023 Guidance Revenue: Q4 of $3.7 billion, versus $4.1 billion last year; Full year of $14.9 billion, versus $16.1 billion last year Diluted EPS: Q4 of $0.86, versus $5.75 last year; Full year of $13.97, versus $24.39 last year Adjusted EPS: Q4 of $4.14, versus $6.77 last year; Full year of $19.94, versus $28.52 last year Free Cash Flow: Q4 of $536 million, versus $548 million last year; Full year of $1.5 billion, versus $2.6 billion last year Additional $1.0 billion share repurchase authorization approved by the Board of Directors Launched liquid biopsy oncology test called Labcorp Plasma Focus, the first new product from the acquisition of Personal Genome Diag

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicking on this link, to receive the dial-in numbers and unique PIN to access the call. The webcast and dial-in are listen-only. It is recommended that parti

Company Updates Full-Year Guidance  Revenue: Q3 of $3.6 billion versus $4.1 billion last year Diluted EPS: Q3 of $3.90 versus $6.05 last year Adjusted EPS: Q3 of $4.68 versus $6.82 last year Free Cash Flow: Q3 of $270 million versus $650 million last year Progressed Clinical Development business spin-off activities Completed transactions to establish long-term relationship with Ascension   Labcorp (NYSE:LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance. "Labcorp made important strategic progress this quarter and is well positioned to deliver sustained value and growth," said Adam Sc

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. 27, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicking on this link, to receive the dial-in numbers and unique PIN to access the call. The webcast and dial-in are listen-only. It is recommended that participants join

Company To Spin-Off Clinical Development Business Revenue: Q2 of $3.7 billion versus $3.8 billion last year Diluted EPS: Q2 of $3.87 versus $4.76 last year Adjusted EPS: Q2 of $4.96 versus $6.13 last year Free Cash Flow: Q2 of $429 million versus $390 million last year Launched innovative diagnostics for skin cancer, neurodegenerative disease, fertility and COVID-19 Full-Year 2022 Guidance: Adjusted EPS raised to $19.00 to $21.25 Labcorp (NYSE:LH), a leading global life sciences company, today announced results for the second quarter ended June 30, 2022, and updated full-year guidance. "Labcorp continued to execute well during the second quarter," said Adam Schechter, chairma

Clinical Development Business to be a Leading, Pure-Play Contract Research Organization with a Comprehensive Set of Clinical Trial Management, Market Access and Technology Capabilities Labcorp Remains a Leader in the Laboratory Market with Highly Complementary, Laboratory-Focused Businesses including Routine and Esoteric Labs, Central Labs and Early Development Research Labs Transaction Designed to Create Value Through Enhanced Strategic and Operational Focus Labcorp to Discuss Spin-off and Second Quarter 2022 Financial Results at 9:00 a.m. ET Today Labcorp (NYSE:LH) (the "Company"), a leading global life sciences company, today announced that its Board of Directors has authorized the

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-800-715-9871 within the U.S. and Canada, or 1-646-307-1963 internationally, using the conference ID 4124787. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

Company Raises Full-Year Revenue and EPS Guidance Revenue: Q1 of $3.9 billion versus $4.2 billion last year Diluted EPS: Q1 of $5.23 versus $7.82 last year Adjusted EPS: Q1 of $6.11 versus $8.79 last year Free Cash Flow: Q1 of $239 million versus $1.1 billion last year Announced initiation of quarterly dividend, with $0.72 per share for the second quarter Entered into several new strategic health system collaborations Full-Year 2022 Guidance: Adjusted EPS improved to $18.25 to $21.00 and Free Cash Flow unchanged at $1.7 billion to $1.9 billion Labcorp (NYSE:LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2022, and up

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the first quarter of 2022 before the market opens on Thursday, April 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-825-4844 within the U.S. and Canada, or 1-631-813-4900 internationally, using the conference ID 2386657. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

Company Provides 2022 Guidance and Longer-Term Outlook (2022-2024) Revenue: Q4 of $4.1 billion, versus $4.5 billion last year; Full year of $16.1 billion, versus $14.0 billion last year Diluted EPS: Q4 of $5.75, versus $9.54 last year; Full year of $24.39, versus $15.88 last year Adjusted EPS: Q4 of $6.77, versus $10.56 last year; Full year of $28.52, versus $23.94 last year Free Cash Flow: Q4 of $548 million, versus $675 million last year; Full year of $2.6 billion, versus $1.8 billion last year Strengthened leading oncology position by agreeing to acquire Personal Genome Diagnostics Inc. Announced yesterday a comprehensive, long-term strategic agreement with Ascension; Arrange

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-825-4844 within the U.S. and Canada, or 1-631-813-4900 internationally, using the conference ID 1756959. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations

Company Raises Full-Year Guidance Revenue: Q3 of $4.1 billion, versus $3.9 billion last year Diluted EPS: Q3 of $6.05, versus $7.17 last year Adjusted EPS: Q3 of $6.82, versus $8.41 last year Free Cash Flow: Q3 of $650 million, versus $709 million last year Enhanced women's health leadership position with acquisition of Ovia Health Full Year 2021 Guidance: Revenue raised to range of 13.0% to 14.0%; Adjusted EPS raised to range of $26.00 to $28.00; Free Cash Flow raised to range of $2.45 billion to $2.60 billion Labcorp (NYSE:LH), a leading life sciences company, today announced results for the third quarter ended September 30, 2021, and raised full-year guidance. "Labcorp del

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the third quarter of 2021 before the market opens on Thursday, October 28, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-2811 internationally, using the conference ID 4893731. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website. An